Renfrew Group International |Renfrew Group International |Renfrew Group International |
  • Home
  • News
  • Case Studies
  • Sectors
    • Services
    • Medical Scientific
    • Product Design
    • Automotive Design
    • Motorcycle Design
    • Engineering Design
  • Gallery
  • About Us
  • Awards
  • Careers
  • Blog
  • Worldwide
    • 中文
    • conception de produits médicaux
  • Contact Us

Oxford Medical Diagnostics appoints Renfrew Group International for the engineering and industrial design of their Breath Ketone Analysis platform

April 22, 2014Medicaladmin
Oxford Medical DiagnosticsNew system aims to reduce the incidence of Diabetic KetoAcidosis.

Oxford Medical Diagnostics (OMD), a leading developer of advanced proprietary methods of analysing volatile organic compounds (VOCs) in breath, has contracted Renfrew Group International (RGi) for the engineering and industrial design of a portable breath analysis platform based upon OMD’s prototype device.

The collaboration will combine OMD’s scientific research expertise with RGi’s design capabilities to further develop an accurate, low-cost, portable and non-invasive breath analysis platform to identify and monitor certain metabolic and infectious diseases by detecting and measuring VOCs in breath.

OMD’s platform is based on the Company’s main proprietary technology, Cavity Enhanced Absorption Spectroscopy (CEAS), which was developed at the University of Oxford. The current prototype device is capable of measuring acetone in breath samples at sub-parts-per-million levels, which is in excess of the sensitivity required to detect acetone levels of patients with Type 1 diabetes.

Oxford Medical DiagnosticsOMD has been awarded SBRI funding and two TSB grants to support this work. The Company is currently performing the next phase of clinical trials in collaboration with an expert team at Addenbrookes Hospital in Cambridge under the direction of Dr Mark Evans.

OMD’s CEO, Dr Ian Campbell, stated: “Appointing RGi is a significant step forward for OMD. Given the robust performance of the prototype in the clinical evaluation we are now in a position to move forward with a design for manufacture.”

Bruce Renfrew, Managing Director of RGi commented: “RGi is delighted to be working with OMD to industrialise this innovative, non-invasive diagnostic platform.”

For more information please visit: http://www.omdiagnostics.com/ui/content/content.aspx?ID=295

The current device is designed for use in Type 1 diabetes, as an aid to diabetes management and to help prevent the onset of Diabetic KetoAcidosis (DKA). In recent months the prototype system was successfully used in its first clinical evaluation, successfully measuring breath acetone from over 100 samples.

Previous post Winners of the British Inventors Project Award 2014 Next post Cromwell ER1 Rescue Helmet for International Rescue

Recent Posts

  • MCHC and Niantic, Inc. Invest in DigiLens for Holographic AR Displays
  • Artificial Pancreas – Reprise
  • The new Brute 500 motorcycle exhibited at Motorcycle Live at the NEC -November 2018
  • Renfrew Group International assist UKDI, with a new type of stretcher
  • Renfrew Group Exhibit at Medica 2018

Archives

News Categories

  • Medical
  • Motorcycle
  • News
  • Product
  • All news list

Contacts

Rocket Studios, Waterside Road
Leicester, LE5 1TL
+ 44(0)116 253 1961
info@renfrewgroup.com
Sign Up Newsletter

News Categories

  • Medical
  • Motorcycle
  • News
  • Product
  • All news list
Email
Facebook
Twitter
LinkedIn
YouTube
Pinterest
ISO-13485
Certified to ISO 13485
© 2019 All rights reserved. Renfrew Group International - terms of use - privacy policy - cookies-policy
Our website uses cookies to improve your user experience. If you continue browsing, we assume that you consent to our use of cookies.OkRead more